JP2023543218A5 - - Google Patents
Info
- Publication number
- JP2023543218A5 JP2023543218A5 JP2023518775A JP2023518775A JP2023543218A5 JP 2023543218 A5 JP2023543218 A5 JP 2023543218A5 JP 2023518775 A JP2023518775 A JP 2023518775A JP 2023518775 A JP2023518775 A JP 2023518775A JP 2023543218 A5 JP2023543218 A5 JP 2023543218A5
- Authority
- JP
- Japan
- Prior art keywords
- expression
- repressor
- dna sequence
- binding
- dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063082555P | 2020-09-24 | 2020-09-24 | |
| US63/082,555 | 2020-09-24 | ||
| US202163242957P | 2021-09-10 | 2021-09-10 | |
| US63/242,957 | 2021-09-10 | ||
| PCT/US2021/051945 WO2022067033A1 (en) | 2020-09-24 | 2021-09-24 | Compositions and methods for inhibiting gene expression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023543218A JP2023543218A (ja) | 2023-10-13 |
| JP2023543218A5 true JP2023543218A5 (https=) | 2024-10-02 |
Family
ID=80845810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023518775A Pending JP2023543218A (ja) | 2020-09-24 | 2021-09-24 | 遺伝子発現を阻害するための組成物及び方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230399640A1 (https=) |
| EP (1) | EP4217477A4 (https=) |
| JP (1) | JP2023543218A (https=) |
| KR (1) | KR20230074525A (https=) |
| AU (1) | AU2021350024A1 (https=) |
| MX (1) | MX2023003424A (https=) |
| WO (1) | WO2022067033A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170151281A1 (en) | 2015-02-19 | 2017-06-01 | Batu Biologics, Inc. | Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer |
| US20190255106A1 (en) | 2016-09-07 | 2019-08-22 | Flagship Pioneering Inc. | Methods and compositions for modulating gene expression |
| US10980836B1 (en) | 2019-12-11 | 2021-04-20 | Myeloid Therapeutics, Inc. | Therapeutic cell compositions and methods of manufacturing and use thereof |
| EP4240367A4 (en) | 2020-11-04 | 2024-10-16 | Myeloid Therapeutics, Inc. | MODIFIED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF |
| WO2022197949A2 (en) | 2021-03-17 | 2022-09-22 | Myeloid Therapeutics, Inc. | Engineered chimeric fusion protein compositions and methods of use thereof |
| BR112023023642A2 (pt) | 2021-05-11 | 2024-01-30 | Myeloid Therapeutics Inc | Métodos e composições para integração genômica |
| WO2023057880A1 (en) * | 2021-10-05 | 2023-04-13 | Glaxosmithkline Intellectual Property Development Limited | Crispr/cas9-based fusion proteins for modulating gene expression and methods of use |
| KR20250077608A (ko) * | 2022-08-19 | 2025-05-30 | 튠 쎄라퓨틱스, 인코포레이티드 | 표적 유전자 억제를 통한 b형 간염 바이러스 조절용 조성물, 시스템 및 방법 |
| KR20250128349A (ko) * | 2022-12-23 | 2025-08-27 | 에피제닉 테라퓨틱스 피티이 리미티드 | 융합체 및 이의 용도 |
| EP4713027A1 (en) | 2023-05-16 | 2026-03-25 | Omega Therapeutics, Inc. | Methods and compositions for modulating methylation of a target gene |
| WO2024238723A1 (en) | 2023-05-16 | 2024-11-21 | Omega Therapeutics, Inc. | Methods and compositions for modulating pcsk9 expression |
| WO2025019742A1 (en) | 2023-07-19 | 2025-01-23 | Omega Therapeutics, Inc. | Methods and compositions for modulating ctnnb1 expression |
| WO2025064469A1 (en) * | 2023-09-18 | 2025-03-27 | Omega Therapeutics, Inc. | Methods for assessing dosage for epigenetic modifying agents |
| WO2025171047A1 (en) * | 2024-02-05 | 2025-08-14 | Bioventures, Llc | Leveraging cancer-evolved resistance mechanisms to enhance ezh2 activity in adoptive t cells |
| WO2025261475A1 (zh) * | 2024-06-21 | 2025-12-26 | 益杰立科(上海)生物科技有限公司 | 靶向血管内皮生长因子的工程化基因转录阻抑工具及用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013266968B2 (en) * | 2012-05-25 | 2017-06-29 | Emmanuelle CHARPENTIER | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
| GB201418965D0 (https=) * | 2014-10-24 | 2014-12-10 | Ospedale San Raffaele And Fond Telethon | |
| WO2017031370A1 (en) * | 2015-08-18 | 2017-02-23 | The Broad Institute, Inc. | Methods and compositions for altering function and structure of chromatin loops and/or domains |
| US9896696B2 (en) * | 2016-02-15 | 2018-02-20 | Benson Hill Biosystems, Inc. | Compositions and methods for modifying genomes |
| US20220380760A1 (en) * | 2018-10-15 | 2022-12-01 | Flagship Pioneering Innovations V, Inc. | Disrupting genomic complex assembly in fusion genes |
| US20220249625A1 (en) * | 2019-01-29 | 2022-08-11 | Flagship Pioneering Innovations V, Inc. | Compositions comprising an endonuclease and methods for purifying an endonuclease |
-
2021
- 2021-09-24 AU AU2021350024A patent/AU2021350024A1/en active Pending
- 2021-09-24 JP JP2023518775A patent/JP2023543218A/ja active Pending
- 2021-09-24 EP EP21873514.0A patent/EP4217477A4/en active Pending
- 2021-09-24 WO PCT/US2021/051945 patent/WO2022067033A1/en not_active Ceased
- 2021-09-24 US US18/246,480 patent/US20230399640A1/en active Pending
- 2021-09-24 KR KR1020237013601A patent/KR20230074525A/ko not_active Withdrawn
- 2021-09-24 MX MX2023003424A patent/MX2023003424A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023543218A5 (https=) | ||
| US12246061B2 (en) | Sequence specific antimicrobials | |
| Huang et al. | Novel oligoamine analogues inhibit lysine-specific demethylase 1 and induce reexpression of epigenetically silenced genes | |
| Dai et al. | Classical HDACs in the regulation of neuroinflammation | |
| JP2022527108A5 (https=) | ||
| Rojewska et al. | PD98059 influences immune factors and enhances opioid analgesia in model of neuropathy | |
| Sinha et al. | PARP1-modulated chromatin remodeling is a new target for cancer treatment | |
| HUP9902103A2 (hu) | Triarilvegyületek | |
| US20180050982A1 (en) | Uses of histone acetyltransferase activators | |
| EP3632901A1 (en) | Histone acetyltransferase activators and uses thereof | |
| PH12022552237A1 (en) | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
| JP2022512974A5 (https=) | ||
| MY200481A (en) | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
| JP2008501316A (ja) | ラクトバシルスｇｇ由来プロバイオティック化合物及びそれらの使用 | |
| US11773394B2 (en) | Antisense drugs against canine ICAM-1 for use in the treatment of inflammation of the buccal cavity | |
| JP2021512929A5 (https=) | ||
| JP2023543056A5 (https=) | ||
| PH12022552712A1 (en) | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
| Urnov et al. | Chromatin organisation and human disease | |
| CN104958286B (zh) | 用于治疗疾病的化合物 | |
| CA3193868A1 (en) | Compositions and methods for inhibiting the expression of multiple genes | |
| WO2023288240A8 (en) | Antisense oligonucleotide (aso) gene inhibition and treatment | |
| JP2025503251A5 (https=) | ||
| EP4595976A1 (en) | Composition for treating cancer containing histone deacetylase inhibitor, and anticancer adjuvant for cancer immunotherapy | |
| EP4438617A1 (en) | Peptide having inhibitory activity against amyloid precursor protein and use thereof |